Cargando…

Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study

OBJECTIVE: Qualitative research exploring patient preferences regarding the mode of treatment administration for psoriatic arthritis (PsA) is limited. We report patient preferences and their reasons across PsA treatment modes. METHODS: In this global, cross-sectional, qualitative study, interviews w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aletaha, Daniel, Husni, M Elaine, Merola, Joseph F, Ranza, Roberto, Bertheussen, Heidi, Lippe, Ralph, Young, Pamela M, Cappelleri, Joseph C, Brown, T Michelle, Ervin, Claire, Hsu, Ming-Ann, Fallon, Lara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293411/ https://www.ncbi.nlm.nih.gov/pubmed/32606613 http://dx.doi.org/10.2147/PPA.S242336

Ejemplares similares

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
por: de Vlam, Kurt, et al.
Publicado: (2022)

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire
por: Coates, L. C., et al.
Publicado: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
por: Taylor, Peter C., et al.
Publicado: (2021)

Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States
por: Bungey, George, et al.
Publicado: (2020)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
por: Coates, Laura C., et al.
Publicado: (2021)

Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey
por: Richette, Pascal, et al.
Publicado: (2022)

Distinguishing rheumatoid arthritis from psoriatic arthritis
por: Merola, Joseph F, et al.
Publicado: (2018)

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
por: Strand, Vibeke, et al.
Publicado: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
por: Coates, Laura C., et al.
Publicado: (2022)

The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis
por: Lucke, Michael, et al.
Publicado: (2016)

The many faces of psoriatic arthritis – a challenge to treatment to target?
por: Aletaha, Daniel
Publicado: (2016)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, Kurt, et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
por: McInnes, Iain B., et al.
Publicado: (2022)

Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists
por: Gottlieb, Alice B., et al.
Publicado: (2022)

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis
por: Cella, David, et al.
Publicado: (2019)

Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis
por: Borst, Carina, et al.
Publicado: (2021)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data
por: Aletaha, Daniel
Publicado: (2009)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
por: Helliwell, Philip, et al.
Publicado: (2018)

RETRACTED ARTICLE: Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis
por: Cella, David, et al.
Publicado: (2019)

Retraction Note to: Content validity and psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with psoriatic arthritis
por: Cella, David, et al.
Publicado: (2019)

Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US
por: Strand, Vibeke, et al.
Publicado: (2016)

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
por: Gossec, Laure, et al.
Publicado: (2020)

An overview of psoriatic arthritis – epidemiology, clinical features, pathophysiology and novel treatment targets
por: Kerschbaumer, Andreas, et al.
Publicado: (2016)

Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR)
por: Schneeweiss, Maria, et al.
Publicado: (2017)

Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries
por: Lucasson, Florian, et al.
Publicado: (2022)

Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
por: Taylor, Peter C, et al.
Publicado: (2020)

Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey
por: Lim, Irwin, et al.
Publicado: (2021)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
por: Mease, Philip J., et al.
Publicado: (2022)

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Clinical Specialty Setting as Determinant of Management of Psoriatic Arthritis: A Cross-Sectional Brazilian Study
por: da Silva Souza, Cacilda, et al.
Publicado: (2022)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey
por: Coates, Laura C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i5vjjbm2qng3eg819465qk8j7i